155 related articles for article (PubMed ID: 38010408)
21. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
22. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer.
Sakamoto T; Kishino M; Murakami Y; Miyatani K; Hanaki T; Shishido Y; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Fujiwara Y
Surg Today; 2024 Jun; ():. PubMed ID: 38822841
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of the cachexia index as a prognostic indicator for patients with gastric cancer.
Nakashima K; Haruki K; Kamada T; Takahashi J; Nakaseko Y; Ohdaira H; Furukawa K; Suzuki Y; Ikegami T
Ann Gastroenterol Surg; 2023 Sep; 7(5):733-740. PubMed ID: 37663966
[TBL] [Abstract][Full Text] [Related]
24. [Clinical Characteristics of 219 Patients with Primary Gastrointestinal Non-Hodgkin's Lymphoma].
Li YY; Hu DZ; Wang YF; Zhao ZG; Cao Z; Zhang YZ; Zhang HL; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):849-854. PubMed ID: 32552946
[TBL] [Abstract][Full Text] [Related]
25. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
26. Etoposide pharmacokinetics impact the outcomes of lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA).
You B; Salles G; Bachy E; Casasnovas O; Tilly H; Ribrag V; Sebban C; Hénin E; Guitton J; Tod M; Freyer G
Cancer Chemother Pharmacol; 2015 Nov; 76(5):939-48. PubMed ID: 26391155
[TBL] [Abstract][Full Text] [Related]
27. Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis.
Zhang MY; Gao F; Zhao YW; Ni BW; Huang HH; Hou J
Hematology; 2022 Dec; 27(1):70-79. PubMed ID: 34957924
[TBL] [Abstract][Full Text] [Related]
28. Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma.
Shimagaki T; Sugimachi K; Mano Y; Onishi E; Iguchi T; Nakashima Y; Sugiyama M; Yamamoto M; Morita M; Toh Y
Ann Gastroenterol Surg; 2023 Nov; 7(6):977-986. PubMed ID: 37927935
[TBL] [Abstract][Full Text] [Related]
29. Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.
Go SI; Kim HG; Kang MH; Park S; Lee GW
BMC Cancer; 2020 May; 20(1):439. PubMed ID: 32423395
[TBL] [Abstract][Full Text] [Related]
30. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil.
Matsunaga T; Saito H; Miyauchi W; Shishido Y; Miyatani K; Morimoto M; Murakami Y; Hanaki T; Kihara K; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Fujiwara Y
BMC Cancer; 2021 Nov; 21(1):1219. PubMed ID: 34774016
[TBL] [Abstract][Full Text] [Related]
31. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
[TBL] [Abstract][Full Text] [Related]
32. Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome.
Terol MJ; Tormo M; Martinez-Climent JA; Marugan I; Benet I; Ferrandez A; Teruel A; Ferrer R; García-Conde J
Ann Oncol; 2003 Mar; 14(3):467-74. PubMed ID: 12598355
[TBL] [Abstract][Full Text] [Related]
33. [Clinical and prognostic analysis of 101 cases of primary gastrointestinal non-Hodgkin's lymphoma].
Song LN; Cen XN; Ou JP; Liang ZY; Qiu ZX; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Yin Y; Sun YH; Liu W; Wang Q; Wang LH; Wang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):387-91. PubMed ID: 23628038
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy.
Alici S; Bavbek S; Basaran M; Onat H
Adv Ther; 2006; 23(4):534-42. PubMed ID: 17050496
[TBL] [Abstract][Full Text] [Related]
35. The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer.
Beypinar I; Demir H; Culha Y; Kaya F
Cureus; 2024 Apr; 16(4):e59301. PubMed ID: 38813321
[TBL] [Abstract][Full Text] [Related]
36. [Analysis for clinicopathological features, therapy and prognosis of 30 elderly patients with non-Hodgkin's lymphoma].
Wang HT; Yang B; Cai LL; Ran HH; Zhang WY; Zhu HL; Yang Y; Li SX; Fan H; Chi XH; Yu RL; Zhang F; Li BL; Lin J; Zhai B; Yao SQ; Lu XC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1464-70. PubMed ID: 24370030
[TBL] [Abstract][Full Text] [Related]
37. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma.
Nakamura N; Hara T; Shibata Y; Matsumoto T; Nakamura H; Ninomiya S; Kito Y; Kitagawa J; Kanemura N; Goto N; Shiraki M; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Ann Hematol; 2015 Dec; 94(12):2043-53. PubMed ID: 26385388
[TBL] [Abstract][Full Text] [Related]
38. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome.
Thieblemont C; Grossoeuvre A; Houot R; Broussais-Guillaumont F; Salles G; Traullé C; Espinouse D; Coiffier B
Ann Oncol; 2008 Apr; 19(4):774-9. PubMed ID: 18065404
[TBL] [Abstract][Full Text] [Related]
39. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.
Tsavaris N; Kosmas C; Zorzos H; Lazaris A; Vadiaka M; Dimitrakopoulos A; Siakantaris MP; Rokana S; Papalambros E; Pangalis GA; Davaris P
Oncol Rep; 2004 Apr; 11(4):899-903. PubMed ID: 15010892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
